What it is
Thymosin Alpha-1 is a thymus-derived immune modulator used in immunology. It is mainly discussed for infection support, hepatitis, and related immune-repair settings.
Evidence boundary
Human evidence exists and the interpretation should stay tied to immune indications. Research-vial handling is not the same as a product label.
Trial evidence
- PMID 40599771 — Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.
- PMID 39648386 — Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
- PMID 38308608 — Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.
- PMID 33076834 — The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Setting | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Conservative immune reference | 300 mcg | 6 U (0.06 mL) | Once daily | 2.1 mg/week |
| Higher immune reference | 500 mcg | 10 U (0.1 mL) | Once daily | 3.5 mg/week |
Conservative immune reference
- Dose
- 300 mcg
- Draw / measure
- 6 U (0.06 mL)
- Frequency
- Once daily
- Weekly total
- 2.1 mg/week
Higher immune reference
- Dose
- 500 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- Once daily
- Weekly total
- 3.5 mg/week
Weekly totals apply only during the active phase. These are reference rows, not a product label.
Titration rules
-
300 mcg is the cautious start.
-
500 mcg is the higher collected step.
-
Keep the schedule tied to the immune goal.
-
Do not turn it into a generic recovery peptide.
-
Infection or inflammation response
-
Tolerability
-
Injection-site reactions
Practical rules
- Rotate sites.